Tvardi Therapeutics up after Piper Sandler starts coverage
Shares of Tvardi Therapeutics TVRD.O rise 4.5% to $27.40
Piper Sandler initiates coverage of TVRD with an "overweight" rating and PT of $78
Piper believes that TVRD's lead drug, TTI-101, is positioned to drive broad improvement with an optimal profile
TTI-101 is uniquely positioned to drive meaningful anti-fibrotic effects for idiopathic pulmonary fibrosis (IPF), a chronic lung disease, at cellular and immune levels - brokerage
TVRD is developing TTI-109 as a next generation STAT3 inhibitor, with investigational new drug application submitted in June 2025
TTI-109 offers a significant pipeline opportunity for TVRD with an optimized product profile and extended coverage to ensure sustained use over time - Piper Sandler
TVRD stock up ~43% YTD, as of last close
Related Articles
This $1 Trillion AI Stock Is Getting Ready for 2026: Is Meta a Good Buy?
When ads and commerce are factored in, Meta is building a long-term platform—in Augmented Reality and smart glasses — to get us closer to the future of AI. This device hardware business is less profitable than ads right now, but it could grow the company’s ecosystem and open up new ways for it to ma
Is SaaS Dead? The Truth Behind the Software Meltdown, the Missing Floor, and the Peak That’s Not Coming Back
TradingKey - A trillion dollars just vanished from software stocks—this piece breaks down who AI is really killing, who quietly benefits, and why cheap SaaS may be the biggest value trap of this cycle.
Best AI Tools for Stock Analysis in 2026 to Boost Your Investment Portfolio
As Artificial Intelligence (AI) continues to enhance everyday decision-making, these tools will allow us to leverage artificial intelligence to analyse stocks and optimise our investment portfolio.
Silver Faces Sixth Consecutive Year of Supply Deficit, How Much Upside Is Left in 2026?
TradingKey - According to the 2026 Silver Market Outlook recently released by the Silver Institute, the current robust performance of the silver market remains supported by solid fundamentals. The report indicates that the global silver market is expected to face a structural supply-demand imbalance
